DUBLIN (August 5, 2021) - SilverCloud Health has partnered with Honeysuckle Health to take proactive steps towards increasing accessibility to digital mental health solutions in Australia.
Registered as a Medical Device Class 1 on the Therapeutic Goods Administration (TGA) in Australia, we are proud to bring our evidence-based and clinically validatedi platform to Australia and support organisations with scalable solutions that deliver measurable results.
Honeysuckle Health is a health services and specialist data science company, with the purpose to create “better pathways to better health for Australians”. Honeysuckle Health offers a range of personalised health programs and services, healthcare analytics, and health service contracting to its participating members, including nib Group.
The strategic partnership opportunity is part of Honeysuckle Health building out a stepped model of mental health support as part of their digital delivery to provide Australians with health opportunities that support positive health outcomes.
SilverCloud Chief Executive Officer, Ken Cahill notes the importance of partnerships to achieve global goals.
“SilverCloud’s expansion into Australia and partnership with Honeysuckle Health is part of our aligned global mission to make mental health solutions more accessible,” Mr Cahill said.
"We are excited to be working alongside them to deliver our flexible evidence-based behavioural and mental health solutions to Australians."
Whilst the SilverCloud platform is clinically proven, it is not designed to replace the care that may already be provided to members by a psychiatrist, psychologist, GP, or specialist.
i Richards, D., Enrique, A., Eilert, N. et al. A pragmatic randomized waitlist-controlled effectiveness and cost-effectiveness trial of digital interventions for depression and anxiety. npj Digit. Med. 3, 85 (2020). https://doi.org/10.1038/s41746-020-0293- https://www.nature.com/articles/s41746-020-0293-8
